Nuvation Bio company information, Employees & Contact Information

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 Business Wire

Nuvation Bio to Participate in Upcoming Investor Conferences Investing News Network

Why I'm Avoiding Nuvation Bio Despite Its Recent FDA Approval (NYSE:NUVB) Seeking Alpha

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer The AI Journal

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update Yahoo Finance

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZI Business Wire

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update Business Wire

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting Business Wire

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025 Business Wire

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Business Wire

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners Business Wire

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer Business Wire

Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer Business Wire

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer Business Wire

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma Business Wire

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer Business Wire

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses Business Wire

Trial begins of NUV-1511 in solid tumors, including mCRPC Urology Times

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update Investing News Network

Nuvation Bio Completes AnHeart Therapeutics Acquisition citybiz

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors Investing News Network

Nuvation Bio CFO Jennifer Fox to Step Down citybiz

Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib Stock Titan

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors Investing News Network

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program Investing News Network

Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development PR Newswire

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer Investing News Network

Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company PR Newswire

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors PR Newswire

Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds PR Newswire